Opportunity for RARE Investors to Lead Ultragenyx Pharmaceutical Securities Fraud Lawsuit

RARE Investors Have an Opportunity to Lead a Class Action

Investors holding Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock have an important deadline looming regarding a class action lawsuit. Those who purchased shares between August 3, 2023, and December 26, 2025, are eligible to act as lead plaintiffs in a burgeoning securities fraud case. The Rosen Law Firm, a prominent global law firm focused on investor rights, has issued a reminder that April 6, 2026, is the final date to step forward as a lead plaintiff.

Background on the Securities Fraud Allegations

The lawsuits arise from claims that Ultragenyx provided investors with misleading information regarding the outcomes of its clinical trials, specifically the Phase III Orbit and Cosmic studies. These studies involved setrusumab (UX 143), positioned as a treatment for Osteogenesis Imperfecta (OI). Allegedly, the statements made by the company's executives suggested a strong confidence in the drug's ability to reduce the fracture rate in OI patients, positing that the clinical trial designs would effectively showcase these capabilities and limit testing variability.

However, the legal filings assert that these optimistic claims were misleading. There are allegations that alongside the assurances of efficacy, material adverse facts regarding the drug's performance were concealed. More explicitly, while setrusumab reportedly increases bone density, this enhancement does not translate into reduced fracture rates—an essential connection that Ultragenyx's management allegedly overstated. As a result, when the truth of the situation became apparent, investors faced substantial financial losses as the stock price fell sharply from its inflated highs.

Taking Action as an Investor

If you purchased shares of Ultragenyx during the defined class period and incurred losses exceeding $100,000, you may be entitled to significant compensation through a class action lawsuit. The Rosen Law Firm operates on a contingency fee basis, meaning investors can join the lawsuit without upfront costs or fees. For those interested in becoming a lead plaintiff, they must act by April 6, 2026, either by reaching out through their website here or calling Phillip Kim, Esq. at 866-767-3653.

Having a legal team with proven experience and a successful track record in handling such cases is crucial. The Rosen Law Firm prides itself on its extensive experience in securities class actions and shareholder derivative litigation, having secured significant settlements for clients in the past. This firm's reputation includes the largest-ever securities class action settlement against a Chinese company and frequent recognition as a leader in this legal realm.

The Importance of Legal Representation

Investors considering participation in this lawsuit are encouraged to carefully select their legal counsel. Many firms making announcements about such cases lack the necessary experience and resources, often serving merely as middlemen who refer clients to actual litigators. The Rosen Law Firm stresses the importance of partnering with qualified attorneys who have consistently demonstrated success in securities litigation.

Before joining the lawsuit, it’s essential to note that as of now, no class has been certified. Until that point, individuals are not represented unless they choose to retain counsel. Remaining an absent class member is an option, but it’s advisable to explore all potential avenues for recovery meticulously. Investors should be aware that willingness to serve as a lead plaintiff is not a prerequisite to share in any eventual recovery. Thus, understanding the implications and processes of these legal proceedings can aid investors in making informed decisions regarding their next steps.

For continuous updates about this case and other legal matters of interest, investors are encouraged to follow the Rosen Law Firm’s progress on social media platforms like LinkedIn, Twitter, and Facebook.

Each investor's situation is unique, and understanding the nuances of the law can significantly impact potential recovery in cases like this one. Those affected should act promptly to safeguard their interests in the wake of the underlying allegations against Ultragenyx Pharmaceutical.